Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 20 citing articles:

Candidate biomarkers in psychiatric disorders: state of the field
Anissa Abi‐Dargham, Scott J. Moeller, Farzana Ali, et al.
World Psychiatry (2023) Vol. 22, Iss. 2, pp. 236-262
Open Access | Times Cited: 156
Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research
Joohyun Yoon, Megan Mayer, Tala Berro, et al.
Pharmaceutical Medicine (2025)
Closed Access | Times Cited: 2
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment
Daniel C. Javitt
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 119-141
Open Access | Times Cited: 64
Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine
Pejman Sehatpour, Dan V. Iosifescu, Heloise M. De Baun, et al.
Biological Psychiatry (2023) Vol. 94, Iss. 2, pp. 164-173
Open Access | Times Cited: 24
Early auditory processing dysfunction in schizophrenia: Mechanisms and implications
Clément Dondé, Joshua T. Kantrowitz, Alice Medalia, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 148, pp. 105098-105098
Open Access | Times Cited: 20
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
Preetika Govil, Joshua T. Kantrowitz
CNS Drugs (2025)
Closed Access
Finding the Right Dose: NMDA Receptor–Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement
Pejman Sehatpour, Joshua T. Kantrowitz
Biological Psychiatry (2024) Vol. 97, Iss. 2, pp. 128-138
Closed Access | Times Cited: 4
Effect-Size Deflation with Increasing Sample-Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action
Joshua T. Kantrowitz, Megan Mayer, Tse‐Hwei Choo, et al.
(2025)
Closed Access
Disturbances in Auditory and Visual Perceptual Function in Schizophrenia: Patterns, Causes, and Consequences
Daniel C. Javitt
Current topics in behavioral neurosciences (2025)
Closed Access
Connecting Neurobiological Features with Interregional Dysconnectivity in Social-Cognitive Impairments of Schizophrenia
Florian W. Adraoui, Linda Douw, Gerard J.M. Martens, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7680-7680
Open Access | Times Cited: 10
Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities
Na Ye, Qi Wang, Yue Li, et al.
Medicinal Research Reviews (2024)
Closed Access | Times Cited: 2
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions
Joshua T. Kantrowitz
CNS Drugs (2021) Vol. 35, Iss. 11, pp. 1153-1161
Closed Access | Times Cited: 13
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry
Joshua T. Kantrowitz, Daniel C. Javitt
Advances in neurobiology (2024), pp. 801-828
Closed Access | Times Cited: 1
Working memory and sensory memory in subclinical high schizotypy: An avenue for understanding schizophrenia?
Sarah M. Haigh, Marian E. Berryhill, Alexandrea Kilgore‐Gomez, et al.
European Journal of Neuroscience (2023) Vol. 57, Iss. 9, pp. 1577-1596
Open Access | Times Cited: 3
Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting
Elizabeth Deckler, Melissa Ferland, Stephanie Brazis, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 11, pp. 924-932
Open Access | Times Cited: 5
Connecting Neurobiological Features with Interregional Dysconnectivity in Social-Cognitive Impairments of Schizophrenia
Florian W. Adraoui, Linda Douw, Gerard J.M. Martens, et al.
(2023)
Open Access | Times Cited: 2
Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia
Daniel C. Javitt
Advances in neurobiology (2024), pp. 411-451
Closed Access
Neuropsychiatric drug development: Perspectives on the current landscape, opportunities and potential future directions
Simon Loïodice, Fulvio D’Acquisto, Pim Drinkenburg, et al.
Drug Discovery Today (2024) Vol. 30, Iss. 1, pp. 104255-104255
Open Access
Augmentation of learning in schizophrenia by D-serine is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study
Viraj Govani, Adithya Shastry, Daniel Iosifescu, et al.
Research Square (Research Square) (2023)
Open Access
Resting state aperiodic slope predicts Research Domain Criteria Social Processes in young typically developing adults
Talitha C. Ford, Aron T. Hill, Nina-Francesca Parrella, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top